The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival.
 
Lakshmi Bhavani Potluri
No Relationships to Disclose
 
Hannah Seah
No Relationships to Disclose
 
Vaishnavi Reddy Bade
No Relationships to Disclose
 
Arthur Krogman
No Relationships to Disclose
 
Shree Acharya
No Relationships to Disclose
 
Andreea Mihaela Negroiu
No Relationships to Disclose
 
Srikanth Talluri
No Relationships to Disclose
 
Lakshmi Manasa Vempati
No Relationships to Disclose
 
Pradyumna Iragavarapu
No Relationships to Disclose
 
Saem Lee
No Relationships to Disclose
 
Mariateresa Fulciniti
No Relationships to Disclose
 
Mehmet Kemal Samur
No Relationships to Disclose
 
Paul G. Richardson
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Karyopharm Therapeutics; Novartis; Oncopeptides; Sanofi; Secura Bio; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Oncopeptides (Inst); Takeda (Inst)
 
Philippe Moreau
Honoraria - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; oncopeptides; Sanofi
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen; oncopeptides; Sanofi
 
Herve Avet-Loiseau
No Relationships to Disclose
 
Kenneth Carl Anderson
Leadership - C4 Therapeutics; Mana Therapeutics; NextRNA; OncoPep; Raqia; starton therapeutics; window therapeutics
Stock and Other Ownership Interests - C4 Therapeutics; Mana Therapeutics; NextRNA; OncoPep; Raqia; STARTON Therapeutics; window therapeutics
Consulting or Advisory Role - amgen; AstraZeneca; Bristol-Myers Squibb; Janssen Oncology; Millennium; oncopeptides; Pfizer; Precision Biosciences; Sanofi
Patents, Royalties, Other Intellectual Property - C4 Therapeutics; Oncopep
 
Rao H. Prabhala
No Relationships to Disclose
 
Nikhil C. Munshi
Stock and Other Ownership Interests - C4 Therapeutics; OncoPep; Raqia
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; BeiGene; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Janssen; Karyopharm Therapeutics; Legend Biotech; Novartis; OncoPep; Raqia; Sebia; Takeda
Patents, Royalties, Other Intellectual Property - Oncopep